Financial Statements

AN2 Therapeutics, Inc. (ANTX)

$3.3

+0.08 (+2.49%)

Cash Flow Statement

All numbers are in thousands
Year XLSX
2022
XLSX
2021
XLSX
2020
XLSX
2019
Operating Cash Flow -33,462-20,484-5,364-2,486
Net Income -40,956-21,543-13,603-5,635
Depreciation & Amortization -692---
Stock-based compensation 4,39197440-
Change in working capital 3,718321,224-10
Other non-cash items 77536,9753,159
Investing Cash Flow -21,771-50,024--
Investment purchases -93,836-77,274--
Sales/Maturities of investments 72,06527,250--
Financing Cash Flow 70,35578,5353,8368,084
Debt repayment -11---
Dividends payments -1,820---
Common Stock Repurchased -11---
Common Stock Issuance 70,36678,5353,8368,084
Other Financing Activites 1,831---
Accounts payables 2,49741781-16
Other working capital 1,221-3851,1436
Cash at beginning of period 12,0974,0705,598-
Cash at end of period 27,21912,0974,0705,598
Net cash flow / Change in cash 15,1228,027-1,5285,598
Free Cash Flow -33,462-20,484-5,364-2,486

AN2 Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes AN2 Therapeutics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.